Hjem › Ikke-småcellet lungekreft › Montana › Billings
Kliniske studier for Ikke-småcellet lungekreft i Billings, MT
17 studier for Ikke-småcellet lungekreft søker deltakere på steder i og rundt Billings (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
RekruttererFase 3
- St. Vincent Frontier Cancer Center-Research ( Site 0105), Billings
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
RekruttererFase 3
- Billings Clinic Cancer Center, Billings
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- Billings Clinic Cancer Center, Billings
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
RekruttererFase 3
- Billings Clinic ( Site 3255), Billings
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekruttererFase 3
- Billings Clinic Cancer Center, Billings
- Saint Vincent Frontier Cancer Center, Billings
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RekruttererFase 3
- St. Vincent Frontier Cancer Center, Billings
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RekruttererFase 3
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana, Billings
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RekruttererFase 3
- SCL Health - Montana, Billings
- SCL Health - Montana, Billings
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
RekruttererFase 2
- Billings Clinic Cancer Center, Billings
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
RekruttererFase 2
- St. Vincent Frontier Cancer Center, Billings
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RekruttererFase 1/2
- Intermountain Health - St. Vincent Frontier Cancer Center, Billings
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- Billings Clinic Cancer Center, Billings
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Billings Clinic Cancer Center, Billings
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2/3
- Billings Clinic Cancer Center, Billings
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Billings Clinic Cancer Center, Billings
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RekruttererObservasjonsstudie
- Billings Clinic Cancer Center, Billings
- Montana Cancer Consortium NCORP, Billings
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Billings
Ikke-småcellet lungekreft-studier i andre byer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andre studier i Billings
- Prostatakreft15 studier
- Lungekreft13 studier
- Brystkreft10 studier
- Eggstokkreft9 studier
- Melanom7 studier
- Kronisk lymfatisk leukemi7 studier
- Akut myelogen leukemi7 studier
- Blærekreft6 studier
- Tykktarmskreft6 studier
- Kolorektal kreft6 studier
- Endetarmskreft5 studier
- Plateepitelcancer i hode og hals4 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.